Open-Label Study of Clarithromycin in Patients with Undifferentiated Connective Tissue Disease

Seminars in Arthritis and Rheumatism

Volumn 36, Issue 2, 2006, Pages 82-87

  Moskowitz, Roland W ^a   Lesko, Mary ^b   Hooper, Michele ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

arthritis therapy; autoimmune disease; macrolides; undifferentiated connective tissue disease

Indexed keywords

ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CLARITHROMYCIN; RHEUMATOID FACTOR;

ADULT; ANALGESIA; ANAMNESIS; ANTIMICROBIAL ACTIVITY; ARTICLE; BLOOD CHEMISTRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DIARRHEA; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; IMMUNOMODULATION; MALE; OUTCOME ASSESSMENT; PAIN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RHEUMATIC DISEASE; SCORING SYSTEM; SYMPTOMATOLOGY; TASTE DISORDER; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VISUAL ANALOG SCALE;

ADULT; AGED; ARTHRITIS; AUTOIMMUNE DISEASES; CHONDROCALCINOSIS; CLARITHROMYCIN; CONNECTIVE TISSUE DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROTEIN SYNTHESIS INHIBITORS; RHEUMATIC DISEASES;

EID: 33749116920     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2006.04.005     Document Type: Article

References (21)

1. Kudoh S. Applying lessons learned in the treatment of diffuse panbronchiolitis to other chronic inflammatory diseases. Am J Med 117 Suppl 9A (2004) 12-19
2. Nagai H., Shishido H., Yoneda R., Yamaguchi E., Tamura A., and Kurashima A. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 58 (1991) 145-159
3. Saviola G., Abdi A., Rossini P., Shams Eddin S., Davoli C., and Taglietti M. Clarithromycin in rheumatoid arthritis patients not responsive to disease-modifying anti-rheumatic drugs: an open, uncontrolled pilot study. Clin Exp Rheumatol 20 (2002) 373-378
4. Greer G.M., and Panush R.S. Incomplete lupus erythematosus. Arch Intern Med 149 (1989) 2473-2476
5. Williams H., Alarcon G., Joks R., Steen V.D., Bulpitt K., Clegg D.O., et al. Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. J Rheumatol 26 (1999) 816-825
6. Moskowitz R.W., and Katz D. Chondrocalcinosis coincidental to other rheumatic disease. Arch Int Med 115 (1965) 680-683
7. Avila P., and Boushey H. Macrolides, asthma, inflammation, and infection. Ann Allergy Asthma Immunol 84 (2000) 565-568
8. Labro M.T. Anti-inflammatory activity of macrolides: a new therapeutic potential?. J Antimicrob Chemother 41 (1998) 37-46
9. Takeshita K., Yamagiski I., Harada M., Otomo S., Nakagawa T., and Mizushima Y. Immunological and anti-inflammatory effects of clarithromycin: inhibition of interleukin 1 production of murine peritoneal macrophages. Drugs Exp Clin Res 15 (1989) 527-533
10. Kahn A., Silfer T., Araujo G., and Remington J. Effects of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents 11 (1999) 121-132
11. Ianaro A., Ialenti A., Maffia P., Sautebin L., Rombola L., Carnuccio R., et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 292 (2000) 156-163
12. Matsuoka N., Eguchi K., Kawakami M., Tsuboi M., Kawabe Y., Aoyagi T., et al. Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells. Clin Exp Immunol 104 (1996) 501-508
13. Lin H., Wang C., Liu C., Yu C., and Kuo H. Erythromycin inhibits beta 2-intergrins (CD11b/CD18) expression, interleukin-8 release and intracellular oxidative metabolism in neutrophils. Respir Med 94 (2000) 654-660
14. Aoshiba K., Nagai A., and Konno K. Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob Agents Chemother 39 (1995) 872-877
15. Inamura K., Ohta N., Fukase S., Kasajima N., and Aoyagi M. The effect of erythromycin on neutrophil apoptosis. Ann Otol Rhinol Laryngol 38 (2000) 124-129
16. Scaglione F., and Rossoni G. Comparative anti-inflammatory effects of roxithromycin, azithromycin, and clarithromycin. J Antimicrob Chemother 41 Suppl B (1998) 47-50
17. Rubin B. Immunomodulatory properties of macrolides: overview and historical perspective. Am J Med 117 Suppl 9A (2004) 2-4
18. Tamaoki J., Kadota J., and Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 17 Suppl 9A (2004) 5-11
19. Majima Y. Clinical implication of the immunomodulatory effects of macrolides on sinusitis. Am J Med 117 Suppl 9A (2004) 20-25
20. Siddiqui J. Immunomodulatory effects on macrolides: implications for practicing clinicians. Am J Med 117 Suppl 9A (2004) 26-29
21. Kvien T., Gaston J., Bardin T., Butrimiene I., Dijkmans B.A., Leirisalo-Repo M., et al. Three month treatment of reactive arthritis with azithromycin: a EULAR double-blind, placebo-controlled study. Ann Rheum Dis 63 (2004) 1113-1119